Aldebaran Capital’s PMV Pharmaceuticals PMVP Stock Holding History

Aldebaran Capital’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$587K	Sell	473,362 -4,626	-1%	-$5.88K	0.45%	31
2025 Q4	$597K	Sell	477,988 -26,140	-5%	-$35K	0.54%	25
2025 Q3	$706K	Sell	504,128 -11,000	-2%	-$15.2K	0.65%	23
2025 Q2	$546K	Sell	515,128 -8,425	-2%	-$8.26K	0.54%	25
2025 Q1	$571K	Buy	523,553 +21,363	+4%	+$29K	0.54%	26
2024 Q4	$758K	Buy	502,190 +63,938	+15%	+$101K	0.72%	26
2024 Q3	$653K	Buy	438,252 +87,009	+25%	+$134K	0.6%	27
2024 Q2	$569K	Buy	+351,243	New	+$633K	0.53%	26

Other funds holding PMVP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Aldebaran Capital's PMVP Position: Q1 2026 in Review

Aldebaran Capital reduced its PMV Pharmaceuticals (PMVP) stake by 0.97% in Q1 2026, selling an estimated $5.88K and leaving 473,362 shares worth $587K. The position accounts for 0.45% of the portfolio, ranked #31.

Aldebaran Capital first reported a position in PMVP in Q2 2024 and has held it in 8 quarters since. The position peaked at $758K in Q4 2024. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

Aldebaran Capital held 473,362 shares of PMV Pharmaceuticals worth $587K as of Q1 2026.
Aldebaran Capital sold 4,626 PMV Pharmaceuticals shares in Q1 2026, an estimated $5.88K.
PMV Pharmaceuticals made up 0.45% of Aldebaran Capital's portfolio in Q1 2026, its #31 holding.
Aldebaran Capital first reported a position in PMV Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Aldebaran Capital's PMV Pharmaceuticals position peaked at $758K in Q4 2024.
69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Aldebaran Capital's 13F filing for Q1 2026, filed 7 May 2026.